SEC Form 4 · accession 0001209191-17-052308
Armata Pharmaceuticals, Inc. · ARMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul C Grint
Officer — Chief Executive Officer · Director
Period of report
Sep 7, 2017
Accepted (ET)
Sep 11, 2017 · 8:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921114
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.91 | Sep 7, 2017 | A | 190,076 | A | — | Sep 6, 2027 | Common Stock | 190,076 | 190,076 | D |
| Stock Option (Right to Buy)F2 | $0.91 | Sep 7, 2017 | A | 285,113 | A | — | Sep 6, 2027 | Common Stock | 285,113 | 285,113 | D |
Explanation of responses
- F11/4th of the shares subject to the option vest on September 7, 2018. The remainder of the shares vest in equal monthly installments thereafter over the next three years.
- F2100% of the shares subject to the stock option shall vest and become exercisable on September 5, 2027, subject to earlier vesting upon the satisfaction of performance criteria.